

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

NCT05012631

Status	RECRUITING
Phase	Phase 2
Sponsor	Children's Hospital Medical Center, Cincinnati
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (17)

- years old or older
- Diagnosis of HbSS or Sbeta0-thalassemia
- Ability to cooperate with and undergo CMR without sedation or anesthesia
- Ability to cooperate with and undergo echocardiogram without sedation or anesthesia
- Patients who are on a stable dose of sickle cell disease-modifying therapy: Hydroxyurea, Voxelotor, L-Glutamine, or Crizanlizumab, for 3 months prior to enrollment will be eligible.

... and 12 more (see full listing online)

Exclusion (1)

- Current chronic transfusion therapy. Patients who received a simple transfusion for an acute event will be eligible 3 months after completion of transfusion

Locations (1 total)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States